Form 4: David J. Mack Reports Changes in Beneficial Ownership of BioXcel Therapeutics, Inc. Stock
SEC Form 4 Filing
Director David J. Mack reports a transaction involving BioXcel Therapeutics, Inc. stock, specifically the vesting and disposal of Restricted Stock Units (RSUs).
Summary
- On March 31, 2025, David J. Mack, a director of BioXcel Therapeutics, Inc., reported a transaction involving Restricted Stock Units (RSUs).
- Mack disposed of 1,693 shares of common stock related to the vesting of RSUs.
- Following the transaction, Mack directly owns 11,852 derivative securities (RSUs).
Sentiment
Score: 5
Explanation: This is a neutral filing related to standard insider transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure related to insider transactions and is required by the SEC to ensure transparency in the market.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it involves a small number of shares related to director compensation.
Key Dates
| Date | Description |
|---|---|
| November 21, 2024 | Reporting Person was granted 20,317 RSUs |
| November 30, 2024 | RSUs vesting in twelve equal installments on the last date of each month beginning on this date |
| March 31, 2025 | Date of transaction: vesting and disposal of 1,693 shares related to RSUs |
| April 01, 2025 | Date of signature for the Form 4 filing |
Keywords
Form 4, BioXcel Therapeutics, BTAI, David J. Mack, Restricted Stock Units, RSUs, Beneficial Ownership, Director, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.